Gliflozins in the management of cardiovascular disease
E Braunwald - New England Journal of Medicine, 2022 - Mass Medical Soc
Gliflozins in Cardiac and Renal Disease Gliflozins—sodium–glucose cotransporter 2
inhibitors—lower blood glucose and glycated hemoglobin in patients with type 2 diabetes …
inhibitors—lower blood glucose and glycated hemoglobin in patients with type 2 diabetes …
Arterial stiffness and cardiovascular risk in hypertension
P Boutouyrie, P Chowienczyk, JD Humphrey… - Circulation …, 2021 - Am Heart Assoc
Arterial stiffness, a leading marker of risk in hypertension, can be measured at material or
structural levels, with the latter combining effects of the geometry and composition of the …
structural levels, with the latter combining effects of the geometry and composition of the …
Pharmacotherapy of type 2 diabetes: An update and future directions
A DeMarsilis, N Reddy, C Boutari, A Filippaios… - Metabolism, 2022 - Elsevier
Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …
social impact for which multiple conventional and novel pharmacotherapies are currently …
[HTML][HTML] SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects
Type 2 diabetes mellitus is a chronic metabolic disease associated with high cardiovascular
(CV) risk. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are the latest class of …
(CV) risk. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are the latest class of …
[HTML][HTML] Arterial stiffness and hypertension in the elderly
S Laurent, P Boutouyrie - Frontiers in cardiovascular medicine, 2020 - frontiersin.org
Hypertension prevalence increases with age. Age and high blood pressure are the two main
determinants of arterial stiffness. In elderly hypertensives, large arteries stiffen and systolic …
determinants of arterial stiffness. In elderly hypertensives, large arteries stiffen and systolic …
Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction: JACC Review Topic of the Week
Abstract Sodium glucose cotransporter-2 (SGLT2) inhibitors improve cardiorenal outcomes
in patients with type 2 diabetes mellitus, chronic kidney disease, and chronic heart failure …
in patients with type 2 diabetes mellitus, chronic kidney disease, and chronic heart failure …
Vascular ageing: moving from bench towards bedside
Prevention of cardiovascular disease (CVD) remains one of the largest public health
challenges of our time. Identifying individuals at increased cardiovascular risk at an …
challenges of our time. Identifying individuals at increased cardiovascular risk at an …
Concept of extremes in vascular aging: from early vascular aging to supernormal vascular aging
S Laurent, P Boutouyrie, PG Cunha, P Lacolley… - …, 2019 - Am Heart Assoc
Laurent et al Early, Normal, and Supernormal Vascular Aging 219 normally defined by the
absence of variables linked to the metabolic syndrome. 21, 22 An alternative way to define …
absence of variables linked to the metabolic syndrome. 21, 22 An alternative way to define …
[HTML][HTML] Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle‐stimulated endothelial senescence and dysfunction: protective effect …
SH Park, E Belcastro, H Hasan, K Matsushita… - Cardiovascular …, 2021 - Springer
Background Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduced cardiovascular risk
in type 2 diabetes patients independently of glycemic control. Although angiotensin II (Ang II) …
in type 2 diabetes patients independently of glycemic control. Although angiotensin II (Ang II) …
Vascular dysfunction of COVID-19 is partially reverted in the long-term
Background: COVID-19 is characterized by severe inflammation during the acute phase and
increased aortic stiffness in the early postacute phase. In other models, aortic stiffness is …
increased aortic stiffness in the early postacute phase. In other models, aortic stiffness is …